Skip to content
Wholesale trade
KZActiveBIN 160740018752
Plans from 2 000 ₸ a month
1/17
High risk
Not present at its registered address
To risks

ТОО "ДИАЛИНА-ФАРМ+"

Director
Уринбаева Райхан Сериковна
Incorporated
22.07.2016
Address
Актюбинская область ул. ДЖАНГИЛЬДИНА АЛИБИ, 159
РНН
061800359783

This is a company preview

Unlock the full report for 1 check — contacts, bank accounts, court cases, government contracts, arrests, licenses and PDF export.

The pack is not a subscription, its checks last 30 days

Risks

1/17
Not present at its registered addressHigh risk

Комитет государственных доходов · data as of 14.01.2026

This assessment is informational and analytical only, based on our internal methodology and open sources; it is not an official government conclusion or a guarantee of reliability.

Procurement signals

Court cases

Arrests & encumbrances

Enforcement proceedings

Certificates

Licenses

Profile

Summary

Full name
ТОВАРИЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ДИАЛИНА-ФАРМ+"
BIN
160740018752
Status
Active
Director
Уринбаева Райхан Сериковна
Registration date
22.07.2016
Activity
Оптовая торговля фармацевтическими товарами, кроме торговли медицинской техникой и ортопедическими изделиями
Legal address
Актюбинская область ул. ДЖАНГИЛЬДИНА АЛИБИ, 159
VAT payer
Yes, since 22.12.2017
КАТО
151013100
РНН
061800359783
КФС
Собственность предприятий без государственного и иностранного участия
КСЕ
Национальные частные нефинансовые корпорации – ОПП
Company size
Малые предприятия
Employees
от 0 до 5 чел.

Activities

1
46461primary

Оптовая торговля фармацевтическими товарами, кроме торговли медицинской техникой и ортопедическими изделиями

Download

Contacts

Change history

Financials

Tax payments

6

By year · ₸

2026
0
2025
294.9K-20%
2024
368.4K+125%
2023
164K-68%
2022
519.2K+4%
2021
501.5K
·0
2026year to date
-20%294.9K
2025
+125%368.4K
2024
-68%164K
2023
+4%519.2K
2022
·501.5K
2021
2026
Tax paid0 ₸
Penalty0 ₸
Fine0 ₸
VAT refund0 ₸
2025
Tax paid294,908 ₸
Penalty63,700 ₸
Fine0 ₸
VAT refund0 ₸
2024
Tax paid368,351 ₸
Penalty0 ₸
Fine0 ₸
VAT refund0 ₸
2023
Tax paid164,049 ₸
Penalty23,000 ₸
Fine0 ₸
VAT refund0 ₸
2022
Tax paid519,179 ₸
Penalty14,000 ₸
Fine0 ₸
VAT refund0 ₸
2021
Tax paid501,524 ₸
Penalty0 ₸
Fine0 ₸
VAT refund0 ₸
Estimated taxable profit

Estimate: corporate income tax ÷ 0%. Not a filing and not revenue — the taxable profit implied by the corporate income tax paid. Actual profit differs by deductions, carried-forward losses and reduced rates.

Download

Financial statements

Premium

Public contracts

What it sells and where

Samruk-Kazyna procurement

Tender bids

Procurement as a customer

Assets

Bank accounts

Management & owners

Leadership

2
  • УР

    Уринбаева Райхан Сериковна

    Director

Former directors

  • АНАБДОЛЛАЕВ НҰРЖАН ҒАЗИЗҰЛЫ
Download

Founders

Accreditations

Employees

Affiliated companies

Premium

Director's involvement in other legal entities

Branches

Relations & mentions

Company networks

Premium

Similar companies

Media mentions

Company summary

ТОО "ДИАЛИНА-ФАРМ+" (BIN 160740018752) is an active legal entity in Актюбинская область, registered in 2016 (10 years on the market). Primary activity — оптовая торговля фармацевтическими товарами, кроме торговли медицинской техникой и ортопедическими изделиями. Per open government registries as of November 6, 2026: 150 government contracts on Портал государственных закупок РК (goszakup.gov.kz) worth 54,911,761 ₸. Automated screening found 1 risk indicator for "ДИАЛИНА-ФАРМ+". Director on record — Уринбаева Райхан Сериковна. Data current as of November 6, 2026.

Information is aggregated from open government registries of Kazakhstan: Министерство юстиции РК, Комитет государственных доходов МФ РК, Верховный Суд РК, Портал государственных закупок РК, АО «Самрук-Казына», Бюро национальной статистики РК, Портал электронного лицензирования. Data is indexed automatically and may lag behind primary sources; the absence of a record does not guarantee the absence of the corresponding facts. This is reference information and does not replace an official extract. Learn more about the methodology and sources — SafeDeal editorial policy.